Ajinomoto Althea, Inc. Chooses QAD Enterprise Edition ERP Solution

SANTA BARBARA, Calif.

QAD Inc. (NASDAQ:QADA) (NASDAQ:QADB), a leading provider of enterprise software and services designed for global manufacturing companies, announced today that Ajinomoto Althea, Inc. (www.altheaCMO.com) has selected QAD Enterprise Edition ERP to support the company’s operations at its San Diego manufacturing facility.

San Diego-based Althea is a fully integrated, contract development and manufacturing organization providing clinical and commercial drug product development services. Althea offers comprehensive services, including: upstream and downstream process development, analytical development, lyophilization cycle, formulation processes, product release and ICH-compliant stability testing.

QAD’s ERP Life Sciences Edition supports Althea by helping them meet DQSA serialization requirements, improve project costing, streamline RF data collection and provide label printing services to automate the production process and reduce errors.

“After conducting a comprehensive review of ERP companies serving the life science industry, we chose the QAD Enterprise Edition ERP solution due to its industry-specific functionality set and ease of use,” said Althea Senior Director of Operational Excellence, Melissa Rosness. “In addition to QAD’s impressive rapid deployment track record, the QAD solution also enables us to operate in a validated, compliant environment which is a critical consideration in the manufacturing of life science products.”

QAD’s solution supports automation of critical quality requirements, including quality control testing, CAPA, and complaint handing. It also provides a qualified environment and the necessary standard operating procedures required to comply with current Good Manufacturing Practices (cGMP) validation requirements. Enhanced controls and audit capabilities, along with eSignature support, help meet the validation mandate.

“We are pleased that Althea has joined the more than 400 life science manufacturing sites that leverage QAD Enterprise Applications,” stated QAD Life Sciences Director Bart Reitter. “Our proven solution ensures that life sciences contract manufacturers are able to work toward becoming effective enterprises, while meeting stringent regulatory demands.”

About QAD – The Effective Enterprise

QAD Inc. (Nasdaq:QADA) (Nasdaq:QADB) is a leading provider of enterprise software and services designed for global manufacturing companies. For more than 35 years, QAD has provided global manufacturing companies with QAD Enterprise Applications, an enterprise resource planning (ERP) system that supports operational requirements, including financials, manufacturing, demand and supply chain planning, customer management, business intelligence and business process management. QAD Enterprise Applications is offered in flexible deployment models as on-premise software, in the cloud with QAD Cloud ERP or in a blended environment. With QAD, customers and partners in the automotive, consumer products, food and beverage, high technology, industrial products and life sciences industries can better align daily operations with their strategic goals to meet their vision of becoming more Effective Enterprises.

For more information about QAD, call +1 805-566-6000, visit www.qad.com.

“QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.

Note to Investors: This press release contains certain forward-looking statements made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding projections of revenue, income and loss, capital expenditures, plans and objectives of management regarding the Company’s business, future economic performance or any of the assumptions underlying or relating to any of the foregoing. Forward-looking statements are based on the company’s current expectations. Words such as “expects,” “believes,” “anticipates,” “could,” “will likely result,” “estimates,” “intends,” “may,” “projects,” “should,” “would,” “might,” “plan” and variations of these words and similar expressions are intended to identify these forward looking statements. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to: evolving demand for the company’s products and companion products; the ability to sustain license and service demand; fluctuation in revenue and earnings in the software industry; the ability to leverage changes in technology; the ability to sustain customer renewal rates at current levels; third party opinions about the company; the reliability of estimates of transaction and integration costs and benefits; competition in our industry; delays in localizing the company’s products for new or existing markets; the ability to recruit and retain key personnel; delays in sales; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. For a more detailed description of the risk factors associated with the company, please refer to the company’s Current Report on Form 8-K dated January 6, 2015 and the periodic reports the company files with the Securities and Exchange Commission thereafter. Management does not undertake to update these forward-looking statements except as required by law.

Markit Strategies
Patrick McLaughlin
734.255.6466
patrickm@markitstrategies.com
or
QAD Inc.
Evan Quinn
Analyst Relations
617.869.7335
industryanalyst@qad.com